Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 3/20 | 0.39 |
| ▸ | HTR1B | P28222 | 3/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4522592 | 0.86 | AAK1 (0.41) | ROCK2ROCK1SMN1; SMN2LMNAAAK1 | |
| SCHEMBL4525125 | 0.86 | HDAC4 (0.47) | ROCK2ROCK1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL4532143 | 0.85 | ROCK2 (0.48) | ROCK2ROCK1SMN1; SMN2LMNAAAK1 | |
| SCHEMBL4519493 | 0.85 | ROCK2 (0.48) | ROCK2ROCK1SMN1; SMN2LMNAAAK1 | |
| SCHEMBL4517728 | 0.80 | MMP2 (0.43) | ROCK2ROCK1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL4528949 | 0.79 | AAK1 (0.42) | ROCK2ROCK1MAPTLMNAAAK1 | |
| SCHEMBL4527223 | 0.78 | AAK1 (0.53) | ROCK2ROCK1SMN1; SMN2MAPTLMNA | |
| SCHEMBL4630929 | 0.77 | ROCK2 (0.57) | ROCK2ROCK1SMN1; SMN2MAPTLMNA | |
| SCHEMBL4525931 | 0.76 | ROCK2 (0.53) | ROCK2ROCK1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL4525453 | 0.76 | ROCK2 (0.53) | ROCK2ROCK1SMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | ROCK2 2/4885ROCK1 1/4885SMN1; SMN2 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.